TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer

Trefoil Factor 3 Is Oncogenic and Mediates Anti-Estrogen Resistance in Human Mammary Carcinoma

(2015) Nagarajan Kannan et al.   NEOPLASIA

Insulin-like Growth Factor-Dependent Proliferation and Survival of Triple-Negative Breast Cancer Cells: Implications for Therapy

(2015) Zoë Davison et al.   NEOPLASIA

Molecular Profiling of Tumor Cells in Cerebrospinal Fluid and Matched Primary Tumors from Metastatic Breast Cancer Patients with Leptomeningeal Carcinomatosis

(2013) M. J. M. Magbanua et al.   CANCER RESEARCH

Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009

(2013) Rebecca H. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

TFF3 Is a Normal Breast Epithelial Protein and Is Associated with Differentiated Phenotype in Early Breast Cancer but Predisposes to Invasion and Metastasis in Advanced Disease

(2012) Ahmed R.H. Ahmed et al.   AMERICAN JOURNAL OF PATHOLOGY

The potential of trefoil proteins as biomarkers in human cancer

(2012) Felicity EB May   Biomarkers in Medicine

Extended adjuvant tamoxifen for breast cancer—a new era?

(2012) Trevor J Powles   LANCET

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)

(2012) Laura Biganzoli et al.   LANCET ONCOLOGY

Trefoil factor family peptides in human saliva and cyclical cervical mucus. Method evaluation and results on healthy individuals

(2011) Mie Hessellund Samson et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

(2010) Myrthe P. P. van Herk-Sukel et al.   BREAST CANCER RESEARCH AND TREATMENT

Fulvestrant - A Novel Endocrine Therapy for Breast Cancer

(2010) S. Johnston et al.   CURRENT MEDICINAL CHEMISTRY

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

(2010) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Issues and updates: evaluating estrogen receptor-α, progesterone receptor and HER2 in breast cancer

(2010) D Craig Allred   MODERN PATHOLOGY

History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target

(2009) R. J. Santen et al.   ENDOCRINE REVIEWS

Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration

(2009) Gail E de Blaquière et al.   ENDOCRINE-RELATED CANCER